neladalkib   Click here for help

GtoPdb Ligand ID: 13214

Synonyms: compound 1 [WO2023196910]
PDB Ligand
Compound class: Synthetic organic
Comment: The chemical structure for neladalkib was obtained from proposed INN list 130 (Feb. 2024), in which the compound is described as an anaplastic lymphoma kinase (ALK) inhibitor with potential antineoplastic action. It is claimed in Nuvalent's patent WO2023196910 [1]. Nuvalent's pipeline declares one ALK inhibitor, NVL-655, so we suspect that this may be neladalkib.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 1
Topological polar surface area 78.81
Molecular weight 452.91
XLogP 2.41
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCN1C2=C(CC3=CN(C)N=C3C4=CC=C(C=C4[C@@H](C)OC5=CC2=CN=C5N)F)C(=N1)Cl
Isomeric SMILES CCN1C2=C(CC3=CN(N=C3C4=C(C=C(C=C4)F)[C@H](OC5=C(N=CC2=C5)N)C)C)C(=N1)Cl
InChI InChI=1S/C23H22ClFN6O/c1-4-31-21-13-8-19(23(26)27-10-13)32-12(2)17-9-15(25)5-6-16(17)20-14(11-30(3)28-20)7-18(21)22(24)29-31/h5-6,8-12H,4,7H2,1-3H3,(H2,26,27)/t12-/m1/s1
InChI Key FWZSCAQEBTVTOM-GFCCVEGCSA-N
Bioactivity Comments
Compound 1 induces regression in an MR619 cholangiocarcinoma (STRN-ALK G1202R) patient-derived xenograft model [1].
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
ALK receptor tyrosine kinase Hs Inhibitor Inhibition ~9.0 pIC50 - 1
pIC50 ~9.0 (IC50 ~1x10-9 M) [1]
Description: inhibitor potency vs. ALK with mutations F1174L, F1174S, R1275Q, T1151M